ArticleBioactive materials2024
3D-printed, citrate-based bioresorbable vascular scaffolds for coronary artery angioplasty.
Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Engineering bioactive citrate-based hydrogels for wound repair: From structure-function design to microenvironmental regulation.Bioactive materials · 2027Review
- Auxetic Stents as a Next Generation Solution for Vascular Diseases-A Review.Cardiovascular engineering and technology · 2026Review
- Additively manufactured reinforced polymeric stents for peripheral artery disease: design, manufacture and performance evaluation.3D printing in medicine · 2026Article
- Recent Advances in 3D-Printed Bioresorbable Vascular Stents: Toward Patient-Specific, Novel-Structured, Functional, and Smart Devices.ACS omega · 2026Review
- Light-Based 3D Printing of Polyesters: From Synthesis to Fabrication.Chemical reviews · 2026Review
- Advancements in 3D Printing and Nanomaterials for Personalized Drug Delivery.Current drug delivery · 2026Review
- Advances in Surface Biofunctionalization and Intelligent Monitoring of Vascular Scaffolds.Research (Washington, D.C.) · 2026Review
- Bioresorbable scaffolds advances, challenges, and future directions.Annals of medicine and surgery (2012) · 2025Review
- Trends in Photopolymerization 3D Printing for Advanced Drug Delivery Applications.Biomacromolecules · 2025Review
- Polydiolcitrate-MoSACS applied materials & interfaces · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Fully bioresorbable vascular scaffolds (BVSs) aim to overcome the limitations of metallic drug-eluting stents (DESs). However, polymer-based BVSs, such as Abbott's Absorb, the only US FDA-approved BVS, have had limited use due to increased strut thickness (157 μm for Absorb), exacerbated tissue inflammation, and increased risk of major cardiac events leading to inferior clinical performance when compared to metallic DESs. Herein we report the development of a drug-eluting BVS (DE-BVS) through the innovative use of a photopolymerizable, citrate-based biomaterial and a high-precision additive manufacturing process. BVS with a clinically relevant strut thickness of 62 μm can be produced in a high-throughput manner, i.e. one BVS per minute, and controlled release of the anti-restenosis drug everolimus can be achieved by engineering the structure of polymer coatings to fabricate drug-eluting BVS. We achieved the successful deployment of BVSs and DE-BVSs in swine coronary arteries using a custom-built balloon catheter and BVS delivery system and confirmed BVS safety and efficacy regarding maintenance of vessel patency for 28 days, observing an inflammation profile for BVS and DE-BVS that was comparable to the commercial XIENCE™ DES (Abbott Vascular).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.